Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 190

1.

Multiresistant Acinetobacter baumannii infections: epidemiology and management.

Garnacho-Montero J, Amaya-Villar R.

Curr Opin Infect Dis. 2010 Aug;23(4):332-9. doi: 10.1097/QCO.0b013e32833ae38b. Review.

PMID:
20581674
2.

Treatment of Acinetobacter infections.

Michalopoulos A, Falagas ME.

Expert Opin Pharmacother. 2010 Apr;11(5):779-88. doi: 10.1517/14656561003596350. Review.

PMID:
20210684
3.

Update on Pseudomonas aeruginosa and Acinetobacter baumannii infections in the healthcare setting.

Navon-Venezia S, Ben-Ami R, Carmeli Y.

Curr Opin Infect Dis. 2005 Aug;18(4):306-13. Review.

PMID:
15985826
4.
5.

Emergence of resistance to carbapenems in Acinetobacter baumannii in Europe: clinical impact and therapeutic options.

Kempf M, Rolain JM.

Int J Antimicrob Agents. 2012 Feb;39(2):105-14. doi: 10.1016/j.ijantimicag.2011.10.004. Epub 2011 Nov 22. Review.

PMID:
22113193
6.

In vitro synergistic activity of colistin with tigecycline or β-lactam antibiotic/β-lactamase inhibitor combinations against carbapenem-resistant Acinetobacter baumannii.

Karaoglan I, Zer Y, Bosnak VK, Mete AO, Namiduru M.

J Int Med Res. 2013 Dec;41(6):1830-7. doi: 10.1177/0300060513496172.

PMID:
24265334
7.

Therapeutic options for Acinetobacter baumannii infections.

Vila J, Pachón J.

Expert Opin Pharmacother. 2008 Mar;9(4):587-99. doi: 10.1517/14656566.9.4.587. Review.

PMID:
18312160
8.

Treatment of multidrug resistant Acinetobacter.

Murray CK, Hospenthal DR.

Curr Opin Infect Dis. 2005 Dec;18(6):502-6. Review.

PMID:
16258323
9.

Rifampicin/imipenem combination in the treatment of carbapenem-resistant Acinetobacter baumannii infections.

Saballs M, Pujol M, Tubau F, Peña C, Montero A, Domínguez MA, Gudiol F, Ariza J.

J Antimicrob Chemother. 2006 Sep;58(3):697-700.

PMID:
16895941
10.

Antibiotic combinations for serious infections caused by carbapenem-resistant Acinetobacter baumannii in a mouse pneumonia model.

Montero A, Ariza J, Corbella X, Doménech A, Cabellos C, Ayats J, Tubau F, Borraz C, Gudiol F.

J Antimicrob Chemother. 2004 Dec;54(6):1085-91. Epub 2004 Nov 16.

PMID:
15546972
11.

Acinetobacter baumannii: a universal threat to public health?

Giamarellou H, Antoniadou A, Kanellakopoulou K.

Int J Antimicrob Agents. 2008 Aug;32(2):106-19. doi: 10.1016/j.ijantimicag.2008.02.013. Epub 2008 Jun 20. Review.

PMID:
18571905
12.

Colistin and rifampicin in the treatment of nosocomial infections from multiresistant Acinetobacter baumannii.

Motaouakkil S, Charra B, Hachimi A, Nejmi H, Benslama A, Elmdaghri N, Belabbes H, Benbachir M.

J Infect. 2006 Oct;53(4):274-8. Epub 2006 Jan 25.

PMID:
16442632
13.

Drug treatment for multidrug-resistant Acinetobacter baumannii infections.

Bassetti M, Righi E, Esposito S, Petrosillo N, Nicolini L.

Future Microbiol. 2008 Dec;3(6):649-60. doi: 10.2217/17460913.3.6.649. Review.

PMID:
19072182
14.

In vitro effects of tigecycline in combination with colistin (polymyxin E) and sulbactam against multidrug-resistant Acinetobacter baumannii.

Ni W, Cui J, Liang B, Cai Y, Bai N, Cai X, Wang R.

J Antibiot (Tokyo). 2013 Dec;66(12):705-8. doi: 10.1038/ja.2013.84. Epub 2013 Aug 28.

PMID:
23981963
15.
16.

In vitro activities of carbapenem/sulbactam combination, colistin, colistin/rifampicin combination and tigecycline against carbapenem-resistant Acinetobacter baumannii.

Song JY, Kee SY, Hwang IS, Seo YB, Jeong HW, Kim WJ, Cheong HJ.

J Antimicrob Chemother. 2007 Aug;60(2):317-22. Epub 2007 May 31.

PMID:
17540672
17.

Colistin resistance of Acinetobacter baumannii: clinical reports, mechanisms and antimicrobial strategies.

Cai Y, Chai D, Wang R, Liang B, Bai N.

J Antimicrob Chemother. 2012 Jul;67(7):1607-15. doi: 10.1093/jac/dks084. Epub 2012 Mar 22. Review.

PMID:
22441575
18.

Multidrug-resistant Acinetobacter infections: an emerging challenge to clinicians.

Jain R, Danziger LH.

Ann Pharmacother. 2004 Sep;38(9):1449-59. Epub 2004 Jul 27. Review.

PMID:
15280512
19.

[Nosocomial pneumonia due to Acinetobacter baumannii].

Cisneros-Herreros JM, Garnacho-Montero J, Pachón-Ibáñez ME.

Enferm Infecc Microbiol Clin. 2005 Dec;23 Suppl 3:46-51. Review. Spanish.

PMID:
16854341
20.

Efficacy of monotherapy and combined antibiotic therapy for carbapenem-resistant Acinetobacter baumannii pneumonia in an immunosuppressed mouse model.

Song JY, Cheong HJ, Lee J, Sung AK, Kim WJ.

Int J Antimicrob Agents. 2009 Jan;33(1):33-9. doi: 10.1016/j.ijantimicag.2008.07.008. Epub 2008 Oct 2.

PMID:
18835761

Supplemental Content

Support Center